Nevro (NVRO) 2024 Wells Fargo Healthcare Conference summary

Strategic review and business outlook

• A strategic review is underway, considering options such as acquisition, merger, private equity, or asset roll-ups, with a decision expected within months rather than years.

• No significant sales force attrition has occurred since the review announcement, attributed to open communication and confidence in team expertise.

• Guidance was lowered by $35–$40 million for the year, reflecting competitive pressures and trial performance, but optimism remains due to upcoming product launches and pipeline diversification.

• The company is focused on accelerating shareholder value and will communicate outcomes of the review process definitively.

Product innovation and pipeline

• Launching AdaptivAI, an enhancement to the IQ platform, within the next 2–3 months, leveraging a 100,000-patient data set for real-time, patient-driven algorithm adaptation.

• AdaptivAI will enable remote patient monitoring and may offer reimbursement opportunities for physicians.

• A new SCS platform is planned for launch in Q1 2026, with further technology introductions in subsequent years, reflecting a diversified R&D pipeline.

• SI joint product integration is progressing, with manufacturing and distribution scaling up.

Market dynamics and competitive landscape

• SCS market is currently growing at mid-single digits for both volume and revenue, with recent growth driven by competitor product launches and replacement cycles.

• Share pressure is mainly from public competitors, with private entrants having minimal impact in the U.S.

• The company is leveraging its unique clinical trial data and high-frequency technology to differentiate in a competitive market.

• Replacements are emerging as a new revenue stream as early implants reach end-of-life.